DRKS00031196招募中不适用
Dynamics of the anti-factor VIII antibody signature duringtreatment with emicizumab - NAVIGATE
niversitätsklinikum Frankfurt, Klinik für Kinder- und Jugendmedizin, Klinische und Molekulare Hämostaseologie0 个研究点目标入组 100 人开始时间: 2023年2月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- one 至 one（—）
- 性别
- All
入选标准
- •Severe congenital hemophilia A (CHA)
- •- Treatment with emicizumab irrespective of any other treatment
- •- Informed consent
排除标准
- •- No therapy with emicizumab
- •- Immunosuppressive therapy
- •- HIV-infection with CD4 cells <200/µl
研究者
相似试验
招募中
不适用
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With EmicizumabSevere Hemophilia ASevere Hemophilia A With InhibitorSevere Hemophilia A Without InhibitorNCT05802836Christoph Königs100
招募中
不适用
Clinical validation of Factor VIII allo-antibody assays in patients with severe hemophilia A (PSTOL 15).severe haemophilia A patients, low titer assay, factor VIII antibodies, negative Bethesda assay, pharmacokineticNL-OMON23098Radboud University Nijmegen Medical Centre150
已完成
不适用
Clinical validation of Factor VIII allo-antibody assays in patients with hemophilia A. The correlation of factor VIII antibodies, measured with different assays, on factor VIII survival in patients with severe haemophilia A.Haemophilia A1006447710005330NL-OMON31749niversitair Medisch Centrum Sint Radboud50
已完成
4 期
This clinical trial is to study Immune Tolerance Induction, by Factor VIII concentrate containing von Willebrand factor, in severe or moderate haemophilia A patients with inhibitors.CTRI/2014/07/004749Sintesi Research6
撤回
不适用
Non Neutralizing Antibodies: Prevalence and CharacterizationHemophilia ANCT01541527University Hospital, Montpellier